FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APP	ROVAL					
OMB Number:	3235-0104					
Estimated average burden						
hours per response:	0.5					

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Smith Andrew P			2. Date of Event Requiring Statement (Month/Day/Year) 01/30/2015		3. Issuer Name and Ticker or Trading Symbol Sucampo Pharmaceuticals, Inc. [SCMP]					
(Last) (First) (Middle) 4520 EAST WEST HIGHWAY, SUITE 300			01/30/2013		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner			If Amendment, Date of Original Filed (Month/Day/Year) Individual or Joint/Group Filing (Check		
(Street) BETHESDA MD 20814				X Officer (give title below) Chief Financial O	Other (spe below) Officer		icable Line) Form filed b	y One Reporting Person y More than One		
(City)	(State)	(Zip)						reporting P	erson	
			Table I - Nor	n-Derivat	ive Securities Beneficially	y Owned				
1. Title of Security (Instr. 4)					eneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)		4. Nature of Indirect Beneficial Ownership (Instr. 5)		
		(e			e Securities Beneficially (nts, options, convertible		s)			
1. Title of Derivat	tive Security (In	•		Is, warra		securitie:	4. Conversion or Exercise	5. Ownership Form:	6. Nature of Indirect Beneficial Ownership (Instr. 5)	
1. Title of Derivat	tive Security (Ir	•	2. Date Exerc	Is, warra	nts, options, convertible 3. Title and Amount of Securit Underlying Derivative Security	securitie:	4. Conversion	Ownership	Beneficial Ownership	
1. Title of Derivat		istr. 4)	.g., puts, cal 2. Date Exerce Expiration Date Date	Is, warra	nts, options, convertible 3. Title and Amount of Securit Underlying Derivative Security	Amount or Number of	4. Conversion or Exercise Price of Derivative	Ownership Form: Direct (D) or Indirect	Beneficial Ownership	
	ck Option (rigl	nt to buy)	2. Date Exerc Expiration Day (Month/Day/) Date Exercisable	is, warra	nts, options, convertible 3. Title and Amount of Securit Underlying Derivative Security Title	Securities ies / (Instr. 4) Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	Beneficial Ownership	
Employee Stoc	ck Option (rigl ck Option (rigl	nt to buy)	2. puts, cal 2. Date Exerc Expiration Do (Month/Day/N Date Exercisable 05/02/2014	Expiration Date	nts, options, convertible 3. Title and Amount of Securit Underlying Derivative Security Title Class A Common Stock	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	Beneficial Ownership	
Employee Stoc	ck Option (rigl ck Option (rigl ck Option (rigl	nt to buy) nt to buy) nt to buy)	Date Exercisable 05/02/2015	Expiration Date 05/02/2021	nts, options, convertible 3. Title and Amount of Security Underlying Derivative Security Title Class A Common Stock Class A Common Stock	Amount or Number of Shares 11,000 11,000	4. Conversion or Exercise Price of Derivative Security 4.41 4.41	Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	Beneficial Ownership	

Explanation of Responses:

- 1. Performance condition for vesting: the fair market value for a share of SCMP common stock must equal or exceed \$16.00 per share over any 30 consecutive trading days.
- 2. Performance conditions for accelerated vesting: one third of the total award may vest prior to the vesting date each time the Compensation Committee approves management's recommendation that certain pre-determined targets have been achieved in one of the three categories of strategic objectives of the Company.

Remarks:

Exhibit List Exhibit 24 - Power of attorney

/s/ Andrew P. Smith 02/04/2015

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

(For Executing Form ID and Forms 3, 4 and 5)

Know all by these presents that the undersigned hereby constitutes and appoints Charles McFalls, Financial Reporting Manager, or delegate, signing individually, the undersigned's true and lawful attorneys-in fact and agents to:

- (1) Prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the Securities and Exchange Commission a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the Securities and Exchange Commission of reports required by Section 16(a) of the Securities Exchange Act of 1934 or any rule or regulation thereunder;
- (2) Prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the Securities and Exchange Commission Forms 3, 4 and 5 (including amendments thereto and joint filing agreements in connection therewith) in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;
- (3) Do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to prepare and execute any such Form 3, 4 or 5 (including amendments thereto and joint filing agreements in connection therewith) and file such Forms with the Securities and Exchange Commission and any stock exchange, self-regulatory association or any other authority; and
- (4) Take any other action of any type whatsoever in connection with the foregoing that, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required of the undersigned, it being understood that the documents executed by the attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as the attorney-in-fact may approve in the attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, and their substitutes, in serving in such capacity at the request of the undersigned, are not assuming (nor is Sucampo Pharmaceuticals, Inc. assuming) any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by Sucampo Pharmaceuticals, Inc., unless earlier revoked by the undersigned in a signed writing delivered to Sucampo Pharmaceuticals, Inc. and the attorneys-in fact. This Power of Attorney revokes any other power of attorney that the undersigned has previously granted to representatives of Sucampo Pharmaceuticals, Inc. and agents acting on its behalf.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of the date written below.

Dated: February 3, 2015 /s/ Andrew P. Smith
Andrew P. Smith